Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Corbus Pharmaceuticals Hldgs Inc (CRBP)

Corbus Pharmaceuticals Hldgs Inc (CRBP)
5.20 x 1,000 6.20 x 500
Pre-market by (Cboe BZX)
6.04 +0.35 (+6.15%) 04/11/25 [NASDAQ]
5.20 x 1,000 6.20 x 500
Pre-market 6.04 unch (unch) 16:00 ET
Quote Overview for Fri, Apr 11th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
5.69
Day High
6.17
Open 5.71
Previous Close 5.69 5.69
Volume 221,900 221,900
Avg Vol 231,560 231,560
Stochastic %K 75.82% 75.82%
Weighted Alpha -74.52 -74.52
5-Day Change +1.02 (+20.32%) +1.02 (+20.32%)
52-Week Range 4.64 - 61.90 4.64 - 61.90
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 73,881
  • Shares Outstanding, K 12,232
  • Annual Sales, $ 0 K
  • Annual Income, $ -40,210 K
  • EBIT $ -49 M
  • EBITDA $ -51 M
  • 60-Month Beta 3.12
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.49

Options Overview Details

View History
  • Implied Volatility 145.80% ( -27.04%)
  • Historical Volatility 66.40%
  • IV Percentile 83%
  • IV Rank 44.12%
  • IV High 248.58% on 02/10/25
  • IV Low 64.65% on 11/21/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 45
  • Volume Avg (30-Day) 35
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 1,774
  • Open Int (30-Day) 2,261

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.26
  • Number of Estimates 7
  • High Estimate -0.77
  • Low Estimate -2.73
  • Prior Year -0.83
  • Growth Rate Est. (year over year) -51.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.64 +30.17%
on 04/07/25
Period Open: 6.88
7.07 -14.60%
on 03/17/25
-0.84 (-12.21%)
since 03/11/25
3-Month
4.64 +30.17%
on 04/07/25
Period Open: 11.79
13.28 -54.52%
on 01/16/25
-5.75 (-48.77%)
since 01/10/25
52-Week
4.64 +30.17%
on 04/07/25
Period Open: 40.00
61.90 -90.24%
on 07/31/24
-33.96 (-84.90%)
since 04/11/24

Most Recent Stories

More News
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

CRBP : 6.04 (+6.15%)
Corbus Pharmaceuticals: Q4 Earnings Snapshot

Corbus Pharmaceuticals: Q4 Earnings Snapshot

CRBP : 6.04 (+6.15%)
Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update

CRBP : 6.04 (+6.15%)
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

CRBP : 6.04 (+6.15%)
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

CRBP : 6.04 (+6.15%)
Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

CRBP : 6.04 (+6.15%)
Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference

CRBP : 6.04 (+6.15%)
Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025

CRBP : 6.04 (+6.15%)
Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CRBP : 6.04 (+6.15%)
Corbus Pharmaceuticals Advances Oncology Research with First Patient Dosed in CRB-601 Clinical Trial for Advanced Solid Tumors

Corbus Pharmaceuticals begins Phase 1 trial for CRB-601, a monoclonal antibody targeting advanced solid tumors.Quiver AI SummaryCorbus Pharmaceuticals Holdings, Inc. recently announced the dosing of the...

CRBP : 6.04 (+6.15%)

Business Summary

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic...

See More

Key Turning Points

3rd Resistance Point 6.72
2nd Resistance Point 6.45
1st Resistance Point 6.24
Last Price 6.04
1st Support Level 5.76
2nd Support Level 5.49
3rd Support Level 5.28

See More

52-Week High 61.90
Fibonacci 61.8% 40.03
Fibonacci 50% 33.27
Fibonacci 38.2% 26.51
Last Price 6.04
52-Week Low 4.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar